

AHA Award Number: 17GRNT33420119

Dear Venkatesh Mani

We are pleased to inform you that the Research Committee of the American Heart Association (AHA) has approved activation of an Award for the period and in the amount indicated below. This Award is contingent upon satisfactory demonstration that alternative funds have not been, nor will be, awarded to this project. AHA policies do not permit mutual funding or supplementation of a project, even when other agencies have reduced budgets.

Award Type: FDA Summer 2016 Grant-in-Aid

Title of Project: Cardiovascular Safety of E-Cigarettes assessed by PET/MRI

The Award begins 01/01/2017 , and has been approved at the level of funding indicated below:

Period 1 Start Date: 1/1/2017, End Date: 12/31/2017, Total: \$77000

Period 2 Start Date: 1/1/2018, End Date: 12/31/2018, Total: \$77000

The Award has been approved for this duration; however, each year of funding is contingent upon adequate progress, and is subject to approval by the Affiliate Board of Directors and availability of funds.

The AHA has a web-based Research Administration System, Grants@Heart, for managing our research applications and Awards. This system is available for use by Principal Investigators and designated institutional officers of currently active AHA research Awards. As the Principal Investigator of a newly funded Award, you need to access this system to electronically submit the forms required to activate your Award. These forms include an Acceptance Form, an Agreement, a Medical Subjects Heading (MeSH) Form, a Subject Use Form and a Project Budget.

The deadline for submitting your Acceptance Form is 12/11/2016, and all other activation forms must be submitted by 12/18/2016.

Should the Research Committee need to convey special policies or provisions to you, these will be included on your Acceptance Form as concerns or contingencies that must be addressed by you prior to Award activation.

These policies and provisions as specified will bind you as an Awardee of the AHA. The approved amount of your Award may be less than the amount requested. If your budget was reduced, your Acceptance Form should explain the budgetary reductions.

Please note: The Agreement must be printed and signed by all required parties and returned to the AHA in hard copy or emailed to AHA via awards@heart.org. A signed copy of your Agreement should be retained for your files, and a copy should be retained by your fiscal office. Your Award is subject to the limitations defined in the Agreement. The AHA reserves the right not to modify the terms and conditions of the Agreement. This Agreement will cover the period and amount as stated above, and you will not be required to submit another Agreement during the term of your Award unless the structure of your Award is altered.

During the tenure of your AHA Award, you should use the online system to submit your annual scientific progress reports and to request Award changes. Scientific progress reports of work accomplished are required annually. Each subsequent year of funding is contingent upon review of a progress report, which is due 12/15 of each interim award period. Scientific reports in the final year are due 12/15. For grant projects, financial reports are due annually from your fiscal office. Check Grants@Heart for due dates. Financial reports are not required for fellowship training grants. AHA payments will be withheld if these reports have not been submitted by the due date. The forms for reporting progress and expenditures (if applicable) can be submitted in Grants@Heart.

The AHA will remit quarterly installments to your institution for your Award. These payments will occur following the end of each quarter via electronic funds transfer. The AHA pays research Awards in the months of January, April, July and October on or around the third Tuesday of the month.

Your research Award was made possible by the dedicated work of people of all ages and backgrounds who volunteer their time and talents to fight heart disease through advocacy efforts and fundraising activities. Please consider joining them. The AHA is a voluntary health agency, and having highly capable volunteers as leaders and decision-makers is crucial to our future success. Supporting research is our No. 1 organizational priority. Without men and women with strong research backgrounds in key leadership positions, our ability to support the most meritorious research could be compromised and that would be tragic. Please contact the AHA at 1-800-AHA-USA-1 or 1-800-242-8721 to find out about volunteer opportunities with the Founders Affiliate or visit us on the web at <http://my.americanheart.org>.



If you have any questions or need assistance with your Award, please contact the AHA Applicant and Awardee Services group via email at Awards@heart.org or by phone at 214-360-6114 . Please reference your AHA Award number at the top of this message.

Congratulations on your AHA Award, and best wishes for a continuing successful career.

Sincerely,

American Heart Association
Founders Affiliate Research Programs

** AHA reserves the right to revise its payment schedule, as it deems necessary, at any time. Awardees and associated Institutions will be notified in advance of any changes to the schedule.*



NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Grant Number: 5R01HL071021-16
FAIN: R01HL071021

Principal Investigator(s):

Zahi A. Fayad, PHD

Project Title: MR/PET Imaging of coronary atherosclerosis

Jessica Ruth Moise
Associate Dean for Sponsored Programs
Icahn School of Medicine at Mount Sinai
Mount Sinai School of Medicine
One Gustave L. Levy Place, Box 1075
New York, NY 100296574

Award e-mailed to: Grants@mssm.edu

Period Of Performance:

Budget Period: 05/01/2019 – 04/30/2020

Project Period: 06/01/2002 – 04/30/2020

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$524,243 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R01HL071021. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Ronald Caulder
Grants Management Officer
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 5R01HL071021-16**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$166,984
Fringe Benefits	\$47,007
Personnel Costs (Subtotal)	\$213,991
Consultant Services	\$9,000
Travel	\$10,000
Other	\$76,297

Federal Direct Costs	\$309,288
Federal F&A Costs	\$214,955
Approved Budget	\$524,243
Total Amount of Federal Funds Obligated (Federal Share)	\$524,243
TOTAL FEDERAL AWARD AMOUNT	\$524,243

AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$524,243
--	------------------

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
16	\$524,243	\$524,243

Fiscal Information:

CFDA Name:	Cardiovascular Diseases Research
CFDA Number:	93.837
EIN:	1136171197A1
Document Number:	RHL071021D
PMS Account Type:	P (Subaccount)
Fiscal Year:	2019

IC	CAN	2019
HL	8475146	\$524,243

NIH Administrative Data:

PCC: HHTATN / OC: 414E / Released: CAULDERR 04/29/2019

Award Processed: 05/05/2019 08:15:53 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01HL071021-16

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5R01HL071021-16

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01HL071021. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: <http://grants.nih.gov/grants/policy/policy.htm#gps>.

A final expenditure Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 120 days of the period of performance end date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, <http://grants.nih.gov/grants/policy/policy.htm#gps>, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) quarterly cash transaction data. A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e., awards to foreign entities and to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level. If the grantee submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported on the final expenditure FFR and the last cash report to PMS, NIH will close the award at the lower amount. This could be considered a debt or result in disallowed costs.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date. The HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>.

This paragraph does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, D42, D43, D71, DP7, G07, G08, G11, K12, K16, K30, P09, P40, P41, P51, R13, R25, R28, R30, R90, RL5, RL9, S10, S14, S15, U13, U14, U41, U42, U45, UC6, UC7, UR2, X01, X02.

Unless an application for competitive renewal is submitted, a Final Research Performance Progress Report (Final RPPR) must also be submitted within 120 days of the period of performance end date. If a competitive renewal application is submitted prior to that date, then an Interim RPPR must be submitted by that date as well. Instructions for preparing an Interim or Final RPPR are at: https://grants.nih.gov/grants/rppr/rppr_instruction_guide.pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the Interim or Final RPPR. *Note that data reported within Section I of the Interim and Final RPPR forms will be made public and should be written for a lay person audience.*

NIH strongly encourages electronic submission of the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission as indicated below.

Email: The final invention statement may be e-mailed as PDF attachments to: NIHCloseoutCenter@mail.nih.gov.

Hard copy: Paper submissions of the final invention statement may be faxed to the NIH Division of Central Grants Processing, Grants Closeout Center, at 301-480-2304, or mailed to:

National Institutes of Health
Office of Extramural Research
Division of Central Grants Processing
Grants Closeout Center
6705 Rockledge Drive
Suite 5016, MSC 7986
Bethesda, MD 20892-7986 (for regular or U.S. Postal Service Express mail)
Bethesda, MD 20817 (for other courier/express deliveries only)

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final RPPR is not required. However, a final expenditure FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Additional Costs

SECTION IV – HL Special Terms and Conditions – 5R01HL071021-16

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

NHLBI FUNDING GUIDELINES

This award is being issued in accordance with the NHLBI FY 2019 Operating Guidelines which can be found at: <https://www.nhlbi.nih.gov/node-general/fy-2019-funding-and-operating-guidelines>

KEY PERSONNEL

In addition to the PI, any absence, replacement, or substantial reduction in effort of the following individual(s) below, requires written prior approval of the National Institutes of Health awarding component.

Dr. Jason Kovacic, Co-Investigator
Dr. Ventakesh Mani, Co-Investigator

GRADUATE STUDENT COMPENSATION

In accordance with the Notice: NOT-OD-02-017 entitled, GRADUATE STUDENT COMPENSATION published on December 10, 2001, in the NIH Guide for Grants and Contracts, total direct costs (salary, fringe benefits and tuition remission) for graduate students are provided at a level not to exceed the NIH maximum allowable amount (zero level of the Ruth L. Kirschstein National Research Service Award stipend in effect at the time of the competing award). Support recommended for future years has been adjusted accordingly, if applicable. The full guide Notice describing the level of compensation allowed for a graduate student can be found at: <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-017.html>.

FOREIGN TRAVEL

Recipients must comply with the requirements of the Fly America Act (49 U.S.C. 40118) which generally provides that foreign air travel funded by Federal funds may only be conducted on U.S. flag air carriers and under applicable Open Skies Agreements.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Sunshine Wilson
Email: wilsonsa2@mail.nih.gov **Phone:** 301-827-8064 **Fax:** 301-451-5462

Program Official: Narasimhan Danthi
Email: ndanthi@mail.nih.gov **Phone:** 301-451-5170 **Fax:** 301-480-1454

SPREADSHEET SUMMARY

GRANT NUMBER: 5R01HL071021-16

INSTITUTION: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Budget	Year 16
Salaries and Wages	\$166,984
Fringe Benefits	\$47,007
Personnel Costs (Subtotal)	\$213,991
Consultant Services	\$9,000
Travel	\$10,000
Other	\$76,297
TOTAL FEDERAL DC	\$309,288
TOTAL FEDERAL F&A	\$214,955
TOTAL COST	\$524,243

Facilities and Administrative Costs	Year 16
-------------------------------------	---------

F&A Cost Rate 1	69.5%
F&A Cost Base 1	\$309,288
F&A Costs 1	\$214,955



NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Grant Number: 5R01HL135878-03
FAIN: R01HL135878

Principal Investigator(s):
Zahi A. Fayad, PhD

Project Title: Ga68-DOTATATE PET imaging of plaque inflammation

Ms. Jessica Moise
Associate Dean for Sponsored Programs
Mount Sinai School of Medicine
One Gustave L. Levy Place, Box 1075
New York, NY 100296574

Award e-mailed to: Grants@mssm.edu

Period Of Performance:

Budget Period: 05/01/2019 – 04/30/2020

Project Period: 05/15/2017 – 04/30/2021

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$703,867 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R01HL135878. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Ronald Caulder
Grants Management Officer
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 5R01HL135878-03**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$194,188
Fringe Benefits	\$54,372
Personnel Costs (Subtotal)	\$248,560
Consultant Services	\$10,000
Travel	\$5,000
Other	\$146,701
Publication Costs	\$5,000

Federal Direct Costs	\$415,261
Federal F&A Costs	\$288,606
Approved Budget	\$703,867
Total Amount of Federal Funds Obligated (Federal Share)	\$703,867
TOTAL FEDERAL AWARD AMOUNT	\$703,867

AMOUNT OF THIS ACTION (FEDERAL SHARE) **\$703,867**

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
3	\$703,867	\$703,867
4	\$792,197	\$792,197

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name: Cardiovascular Diseases Research
CFDA Number: 93.837
EIN: 1136171197A1
Document Number: RHL135878A
PMS Account Type: P (Subaccount)
Fiscal Year: 2019

IC	CAN	2019	2020
HL	8475146	\$703,867	\$792,197

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: HHTATN / **OC:** 414E / **Released:** CAULDERR 04/10/2019
Award Processed: 04/12/2019 05:50:27 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01HL135878-03

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5R01HL135878-03

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget

- period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01HL135878. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Additional Costs

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

REMOVE HUMAN SUBJECTS RESTRICTION

This award rescinds the human subjects restriction placed on the Notice of Award issued May 10, 2018.

NHLBI FUNDING GUIDELINES

This award is being issued in accordance with the NHLBI FY 2019 Operating Guidelines which can be found at: <https://www.nhlbi.nih.gov/node-general/fy-2019-funding-and-operating-guidelines>

CONSORTIUM/CONTRACTUAL

This award includes funds awarded for consortium activity with with Memorial Sloan Kettering Cancer Center. The recipient, as the direct and primary recipient of NIH grant funds, is accountable to NIH for the performance project, the appropriate expenditures of grant funds by all parties, and all other obligations of the recipient, as specified in the NIH Grants Policy Statement. In general, the requirements that apply to the recipient, including the intellectual property requirements also apply to consortium participant(s)

FOREIGN TRAVEL

Recipients must comply with the requirements of the Fly America Act (49 U.S.C. 40118) which generally provides that foreign air travel funded by Federal funds may only be conducted on U.S. flag air carriers and under applicable Open Skies Agreements.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Sunshine Wilson

Email: wilsonsa2@mail.nih.gov **Phone:** 301-827-8064 **Fax:** 301-451-5462

Program Official: Narasimhan Danthi

Email: ndanthi@mail.nih.gov **Phone:** 301-451-5170 **Fax:** 301-480-1454

SPREADSHEET SUMMARY

GRANT NUMBER: 5R01HL135878-03

INSTITUTION: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Budget	Year 3	Year 4
Salaries and Wages	\$194,188	\$194,188
Fringe Benefits	\$54,372	\$54,372
Personnel Costs (Subtotal)	\$248,560	\$248,560
Consultant Services	\$10,000	\$10,000
Travel	\$5,000	\$5,000
Other	\$146,701	\$198,813
Publication Costs	\$5,000	\$5,000
TOTAL FEDERAL DC	\$415,261	\$467,373
TOTAL FEDERAL F&A	\$288,606	\$324,824
TOTAL COST	\$703,867	\$792,197

Facilities and Administrative Costs	Year 3	Year 4
F&A Cost Rate 1	69.5%	69.5%
F&A Cost Base 1	\$415,261	\$467,373
F&A Costs 1	\$288,606	\$324,824